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Abstract
Background: Estrogen receptor a (ERa) has been shown to protect against atherosclerosis. Methylation of the ERa gene can
reduce ERa expression leading to a higher risk for cardiovascular disease. Recently, microRNAs have been found to regulate
DNA methyltransferases (DNMTs) and thus control methylation status in several genes. We first searched for microRNAs
involved in DNMT-associated DNA methylation in the ERa gene. We also tested whether statin and a traditional Chinese
medicine (San-Huang-Xie-Xin-Tang, SHXXT) could exert a therapeutic effect on microRNA, DNMT and ERa methylation.
Methodology/Principal Findings: The ERa expression was decreased and ERa methylation was increased in LPS-treated
human aortic smooth muscle cells (HASMCs) and the aorta from rats under a high-fat diet. microRNA-152 was found to be
down regulated in the LPS-treated HASMCs. We validated that microRNA-152 can knock down DNMT1 in HASMCs leading
to hypermethylation of the ERa gene. Statin had no effect on microRNA-152, DNMT1 or ERa expression. On the contrary,
SHXXT could restore microRNA-152, decrease DNMT1 and increase ERa expression in both cellular and animal studies.
Conclusions/Significance: The present study showed that microRNA-152 decreases under the pro-atherosclerotic
conditions. The reduced microRNA-152 can lose an inhibitory effect on DNA methyltransferase, which leads to
hypermethylation of the ERa gene and a decrease of ERa level. Although statin can not reverse these cascade
proatherosclerotic changes, the SHXXT shows a promising effect to inhibit this unwanted signaling pathway.
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Introduction
Atherosclerosis is the major pathogenesis of cardiovascular disease
that causes morbidity and mortality in industrialized countries [1]. This
progressive multi-factorial process involves cellular signaling pathways
[2–4], inflammatory mediators, growth factors, and adhesion
molecules [5], [6]. Risk factors such as unhealthy dietary habits, aging
and smoking contribute to the development of cardiovascular disease
through increasing blood lipid levels and inflammation in the arterial
wall. Eventually, arterial smooth muscle cells migrate and proliferate
leading to atherosclerotic plaque formation and atherosclerosis
development [7], [8]. Recently, DNA methylation has been implicated
as a novel risk factor for atherosclerosis [9], [10].
DNA methylation is an important epigenetic modification on
chromosomes that plays a significant role in the regulation of gene
transcription [11]. When the cytosine and guanine contents are
greater than 50% in the DNA sequence of humans, the high CG
content regions can be hypermethylated causing transcriptional
silencing [12]. Increasing evidence shows that global DNA
hypomethylation is associated with gene transcriptional activity
in the pathogenesis of cardiovascular diseases, including athero-
sclerosis [13–16]. Hiltunen et al. reported global DNA hypo-
methylation in the proliferating vascular smooth muscle cells
(VSMCs) of human atherosclerotic plaque [9].
Estrogen receptor a (ERa) has been reported to protect against
atherosclerosis and aging in the cardiovascular system [17], [18].
Increased expression of the ERa gene can reduce the proliferation
of VSMCs [19], [20]. DNA methylation in the promoter region of
the ERa gene can reduce transcription of ERa leading to a higher
risk for several cardiovascular diseases [18].
It is known that DNA methylation is catalyzed by DNA
methyltransferases (DNMTs), namely DNMT1, DNMT3a and
DNMT3b. Methytransferases use a reactive methyl group bound
to sulfur in S-adenosyl methionine as the methyl donor. DNMT1 is
the most abundant DNA methyltransferase in mammalian cells and
the key maintenance enzyme for hemimethylated DNA during DNA
replication of various cancer cells [21]. DNMT3a and DNMT3b are
responsible for establishing de novo methylation and both enzymes
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evidence and our previous study showed that microRNAs (miRs),
which are noncoding RNAs, can be involved in the promoter
methylation of CpG islands by targeting DNMTs 39UTR [23–27].
Thus, we first aimed to search for miRNAs involved in DNMT-
associated DNA methylation in the ERa gene.
Statin is a widely used lipid-lowering drug with multiple effects on
the cardiovascular system [28]. Statin has been shown to have
multiple mechanisms to reduce the cardiovascular risk including the
anti-inflammation effects [29] and the inhibition of neointimal
proliferation [30], [31]. We previously also found San-Huang-Xie-
Xin-Tang (SHXXT), a traditional Chinese medicine, has several
beneficial anti-atherosclerotic and anti-inflammatory effects [32]. In
the present study, we also tested whether statin and SHXXT can
regulate DNA methylation in the ERa gene as our second aim.
Results
ERa expression in LPS-treated HASMCs and HF feeding in
rats
In our previous study, LPS (100 mg/ml) significantly induced
the cell proliferation, migration and inflammation. In this study,
we first found that LPS treatment significantly decreased ERa
mRNA level and protein level at 48 h and 72 h (Fig. 1A and 1B).
Furthermore, ERa expression can also be restored by SHXXT in
a dose-dependent manner (Fig. 1A and 1B). However, simvastatin
(1 mM) treatment had no effect on the decreased ERa at 48 h or
72 h (Fig. 1C). In order to confirm that the SHXXT effect on
increasing ERa expression, we compared the mRNA and protein
expression of the ERa gene in the aorta between the HF diet-fed
SD rats with and without treatment of SHXXT. After 12 weeks,
the ERa mRNA and protein levels were decreased in the HF diet-
fed group as compared with the normal diet group (Fig. 2A and
2B).
DNMT1 expression in LPS-treated HASMCs
For the global methylation pattern, we found that the
proportion of methylation in the Alu elements maintained at
,16% in HASMCs (measured at 48 h and 72 h) prior to LPS
treatment. The proportion of methylation was substantially
decreased to 5% at 72 h, although it was only decreased from
16% to 13% at 48 h after LPS treatment.
Since DNMT1 is the major enzyme for DNA methylation in
mammals, we focused on this DNMT and tried to elucidate the
Figure 1. mRNA and protein expression of ERa in the HASMCs treated with LPS, and the change of promoter methylation in
HASMCs. (A) HASMCs were treated with LPS (100 ng/mL) and SHXXT (0.2–0.6 mg/ml) for 48 h and 72 h. The mRNA expression of ERa after LPS and
SHXXT treatment was detected by real time PCR and normalized to the housekeeping gene GAPDH, and (B) the protein level of ERa after LPS and
SHXXT treatment was detected by Western blot and normalized to the housekeeping gene GAPDH. (C) ERa mRNA and protein level after simvastatin
(1 mM) treatment were detected by real-time PCR and Western blot at 48 h and 72 h. ** P,0.01 versus the control group. Data represents mean 6 SD
from 3 independent experiments performed in triplicates.
doi:10.1371/journal.pone.0030635.g001
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of DNMT1 mRNA expression and protein levels in HASMCs
were found at 48 h and 72 h after the treatment of LPS. When
adding SHXXT (dose between 0.2 to 0.6 mg/ml), the mRNA and
protein expression of DNMT1 were substantially reduced after
incubation for 48 h and 72 h. On the contrary, neither mRNA
nor protein level changed by treating simvastatin (Fig. 3C), which
suggests simvastatin does not influence DNMT1-associated DNA
methylation. Similar to the results from the cellular studies,
DNMT1 expression in the aorta of SD rats was significantly
increased in the HF-diet group and decreased by SHXXT (Fig. 3D
and 3E). Therefore, we demonstrated a consistent change between
ERa and DNMT1, and found a potential therapeutic effect of
SHXXT.
Gain of ERa by DNMT1 knockdown
To further confirm that DNMT1 can influence ERa expression,
we used shRNA to knock down the DNMT1 gene. The RNA
inference caused a decrease of DNMT1 mRNA expression and
protein expression by 57.3% and 58.2% respectively (Fig. 4A and
4B). When DNMT1 was inhibited, the mRNA and protein levels
of ERa were simultaneously increased by 4.33- and 2.32-fold,
respectively (Fig. 4A and 4B). These results clearly show that ERa
gene can be silenced by DNMT1.
ERa methylation in LPS-treated HASMCs and HF fed rats
To determine if ERa locus undergoes promoter hypermethyla-
tion in LPS-treated HASMCs, we checked the methylation status
of the CpG island located in the first exon of ERa gene (Fig. 5A)
by the bisulfite specific PCR and sequencing (BSP) as well as
methylation-specific PCR (MSP). We first measured the methyl-
ation degree of 24 CpG sites in exon 1 (nucleotides 146–354) by
the BSP assay [33]. At 48 h and 72 h after LPS treatment, the
methylation percentage was increased (57% and 77%, respective-
ly) as compared with the control group (40% and 49%,
respectively; Fig. 5B) in overall 24 CpG sites. Although we also
found that the DNA methylation status of ERa can be reversed by
SHXXT treatment, but the drug effect mainly occurred at 72 h
(55%). In the MSP assay, we found that DNA methylation status
in the ERa exon 1 was also increased by LPS, and SHXXT
partially reversed LPS-induced DNA hypermethylation at 48 h
and 72 h (Fig. 5C). These data suggested that ERa exon 1
hypermethylation does occur in LPS-induced HASMCs and affect
ERa expression. In order to confirm that the SHXXT effect on
reducing ERa hypermethylation, we compared the methylation
status of the ERa gene in of the aorta between the HF diet-fed SD
rats with and without treatment of SHXXT. After 12 weeks,
SHXXT could significantly reverse HF diet-induced DNA
hypermethylation of the ERa gene (Fig. 5D).
miR-152 expression in LPS-treated HASMCs
To identify the atherosclerosis-related miRNAs, we used the
miRNA arrays (OneArray microRNA expression profiling micro-
arrays based on the latest miRBase release-version 17; Phalanx
Biotech Group, Taiwan) to survey the miRNA expression levels
between HASMCs treated and untreated with LPS (100 ng/mL).
This commercial array used spotted probes to interrogate 1087
human miRNAs. Among 1,087 surveyed miRNAs, the expression
level of miR-152 was decreased by 2.3-fold when HASMCs were
treated with LPS for 24 h (data not shown). Subsequent real-time
PCR experiment confirmed that LPS can decrease miR-152
expression at 48 h and 72 h (P=0.0015 and 0.006; Fig. 6A).
Figure 2. The expression of ERa in the aorta of the Sprague-Dawley rats under a high fat diet. In addition to a normal diet, rats under a
high fat diet were treated with SHXXT (30 mg/kg/day) or placebo (water) for 12 weeks. (A) The ERa mRNA expression of each group (n=6) was
detected by real time PCR and normalized to GAPDH. Data represents mean 6 SD. (B) The protein level of ERa of each group was detected and
normalized to GAPDH. The number of SD rat in each group is 6. Data represents mean 6 SD.
doi:10.1371/journal.pone.0030635.g002
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bind to the 39 untranslated region (UTR) of DNMT1. Accord-
ingly, we speculated that miR-152 may be involved in DNMT1-
associated DNA methylation in the cardiovascular system.
Furthermore, our cellular studies showed that miR-152 levels
can be induced by SHXXT in a dose-dependent manner, but
cannot be induced by simvastatin for 48 h or 72 h (Fig. 6B). In the
aorta of the SD rats, we confirmed that the miR-152 expression
was down-regulated in the HF-diet group, and it can be up-
regulated after 12-week treatment of SHXXT (n=6; Fig. 6C).
Gain and loss functions of ERa by miR-152
To prove that miR-152 can regulate ERa gene expression via
the suppression of DNMT1, we transfected the miR-152
precursor or inhibitor into the LPS-treated HASMCs. The
results showed that the DNMT1 protein levels were reduced and
consequently ERa protein levels were up-regulated by miR-152
precursor at 72 h (100 nM; Fig. 7A). On the contrary, DNMT1
protein levels were increased and consequently ERa protein
levels were down-regulated by miR-152 inhibitor at 72 h
(100 nM). These findings indicate that miR-152 indirectly up-
regulated ERa expression through its binding to DNMT1. MSP
analysis also showed that DNA methylation at ERa was reduced
by miR-152 precursor in the LPS-treated cells (Fig. 7B).
However, DNA methylation at ERa was increased by miR-152
inhibitor. Therefore, we demonstrated a consistent change
between DNMT1 and ERa methylation by the change of miR-
152 levels.
Figure 3. DNMT1 expression in LPS-induced HASMCs and the aorta of the rats under a high fat diet. (A) HASMCs were treated with LPS
(100 ng/mL) and SHXXT (0.2–0.6 mg/ml) for 48 h. DNMT1 mRNA expression were examined by real-time quantitative PCR and normalized to RU6B.
(B) DNMT1 protein in LPS-treated HASMCs measured by Western blot at 48 h and 72 h. (C) DNMT1 mRNA and protein level after the treatment of
simvastatin for 48 h and 72 h. ** P,0.01 versus the control group. Data represents mean 6 SD from 3 independent experiments performed in
triplicates. (D and E) The mRNA expression and protein level of DNMT1 of the rat aorta under a normal diet and a high-fat diet with or without SHXXT
(30 mg/kg/day) for 12 weeks. The upper panel of Figure 3E shows the western blotting data and lower panel shows the quantification of western
blotting. The number of SD rat in each group is 6.
# P,0.05 versus control, ** P,0.01 versus LPS group. Data represents mean 6 SD.
doi:10.1371/journal.pone.0030635.g003
miR-152 on ERa Expression
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migration
To further examine whether miR-152 influences HASMC
phenotypes through the change of ERa expression, the cell
proliferation and migration were assessed at 48 h and 72 h after
transfecting miR-152 precursor or inhibitor into the cells. The
results demonstrated that the transfected miR-152 precursor
resulted in a concentration-dependent reduction of cell prolifer-
ation in the LPS-treated HASMCs at 48 h and 72 h (Fig. 7C;
P,0.01). However, miR-152 did not influence HASMC migration
at 48 or 72 h (data not shown). These results also suggested that
miR-152 has an anti-atherosclerotic effect by decreasing cell
proliferation.
Discussion
Increasing evidence has revealed that the ERa protein has an
atheroprotective effect and methylation in the ERa gene can cause
atherosclerosis [17], [18]. However, the role of microRNAs in the
regulation of ERa expression has not been extensively explored.
The present study showed that miR-152 can down regulate
DNMT1 which in turn inhibits methylation in the promoter of the
ERa gene leading to higher ERa expression. Therefore, we
identified that miR-152 has an anti-atherosclerotic effect via its
effect on the increase of ERa expression. We also used LPS to
induce hypermethylation of the ERa gene in HASMCs. Although
statin failed to reverse the hypermethylation status in the ERa
gene, the traditional Chinese medicine (SHXXT) partially
recovered LPS-induced DNA hypermethylation. Furthermore,
our animal studies confirmed the therapeutic effect of this Chinese
medicine. Again, statin did not have any effect on increasing miR-
152 but SHXXT could enhance miR-152 expression. Unfortu-
nately, we did have available human samples to compare miR-152
concentrations between atherosclerotic and non-atherosclerotic
tissues. Taken together, the present study not only identified a
novel mechanism to regulate ERa expression but also provided
data for the Chinese medicine SHXXT in the context of
epigenetic therapy in the context of atherosclerosis and cardio-
vascular disease.
It is well known that estrogen has directly protective effect on
the cardiovascular system [17], [34], [35]. Two types of ER (a
and b subtypes) have been identified in VSMCs and endothelial
cells. Several studies have shown that estrogen inhibits the
proliferation and migration of VSMCs via ERa binding [17],
[35], [36]. Furthermore, the anti-atherosclerotic effects of ERa
also can be influenced by the methylation status in its promoter
Figure 4. Expression of ERa after knocking down DNMT1. LPS-treated HASMCs were transfected with shRNAs (6 mg DNA per 10
5 cells)
specifically targeting DNMT1. The data were obtained at 48 h post-transfection of shRNAs. (A) The mRNA levels of DNMT1 and ERa were examined
with real-time quantitative PCR. Data represents mean 6 SD. (B) Protein levels of DNMT1 and ERa were examined by specific antibody.
doi:10.1371/journal.pone.0030635.g004
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ERa gene is regulated by epigenomic mechanism and micro-
RNA.
Newman [37] first proposed that DNA hypomethylation is
involved in the development of cardiovascular disease. Increased
plasma homocysteine and S-adenosylhomocysteine (SAH) are
associated with the inhibition of methyltransferases, which causes
global DNA hypomethylation in VSMCs [38], [39], peripheral
white blood cells [39] and atherosclerotic lesions [40]. More solid
evidence from animal studies suggests that cellular proliferation is
associated with global DNA hypomethylation and DNMT1
overexpression in atherosclerotic lesions [39]. Theoretically,
over-expressed DNMT1 should cause DNA hypermethylation,
but the paradoxical finding of increased global DNA hypomethy-
lation and DNMT1 overexpression was reported in previous
studies [39]. Therefore, there must be other mechanisms
regulating DNA methylation, and in the present study we cannot
rule out the involvement of these undiscovered mechanisms in
ERa hypermethylation. Indeed, co-existence of global hypo-
methylation and hypermethylation in particular genes have been
reported in the atherosclerosis [13]. The DNMT family can be
regulated by several miRs such as miR-29b, miR-148a and miR-
152 [23–25,27]. Given that epigenetic therapy has been
advertised, our finding of SHXXT’s effect on influencing
microRNA and DNA methylation may offer a different approach
in conjunction with statin for a better treatment for cardiovascular
diseases.
In conclusion, the present study showed that the level of miR-
152 decreases under the pro-atherosclerotic stimulations. The
reduced miR-152 can lose an inhibitory effect on DNA
methyltransferase, which contributes to hypermethylation of the
ERa gene. Once hypermethylation takes place in the promoter of
the ERa gene, atherosclerosis can be promoted. Although statin
cannot reverse these cascade proatherosclerotic changes, the
Chinese medicine, SHXXT, shows a potential effect to inhibit
such an unwanted signaling pathway.
Figure 5. Methylation of the ERa gene in HASMCs induced by LPS with or without SHXXT treatment. (A) Schematic diagram of the
distribution of ERa exon I CpG islands in HASMCs (GenBank accession no. X03635.1 G1:31233) are shown. Black and white arrows indicated the PCR
primer pair of methylation specific PCR (MSP) and bisulfite sequencing PCR (BSP), respectively. (B) Exon 1 of the ERa methylation status was analyzed
by MSP at 48 h and 72 h. Electrophoresis showed methylation-specific PCR products from three conditions (Control, LPS treatment and LPS plus
SHXXT treatment).UM: unmethylated; M: methylated ERa. (C) PCR primers specific to unmethylated and methylated bisulfite-modified DNA were
used to amplify exon 1 of the ERa gene in LPS-induced HASMCs and SHXXT treatment. Amplified PCR products were cloned, and six individual clones
were sequenced to determine the methylation state of the 24 CpGs within the amplified region. Open and filled circles indicate that the CpG site is
unmethylated or methylated, respectively. Each row represents one clone. (D) Exon 1 of the ERa methylation status of the rat aortas were analyzed by
MSP. UM: unmethylated; M: methylated ERa.
doi:10.1371/journal.pone.0030635.g005
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HASMC culture and treatment
Human aortic smooth muscle cells (HASMCs, cryopreserved
tertiary cultures; Cascade Biologics, Inc.,OR, USA) were grown in
culture flasks in smooth muscle cell growth media (Medium 231,
Cascade Biologics, Inc., OR, USA). The smooth muscle cell
growth medium consisted of fetal bovine serum (FBS, 5%), human
epidermal growth factor (10 ng/ml), human basic fibroblast
growth factor (3 ng/ml), insulin (10 mg/ml), penicillin (100
units/ml), streptomycin (100 pg/ml), and Fungizone (1.25 mg/
ml). The cells were incubated at 37uC in a humidified 5% CO2
atmosphere. HASMCs were subcultured when the cells were
about 70–80% confluence. Passages 4 to 9 were used for
experiments. Lipopolysaccharide (LPS; 100 ng/mL) was used to
induce an atherogenic change in HASMCs. Before LPS treatment,
cells were grown under HASMC medium without FBS for 24 h.
Cells were then incubated at 37uC for 24 h in the presence of LPS.
SHXXT contains three components: Coptidis rhizome (rhizomes of
Coptis chinesis Franch; CR), Scutellariae radix (roots of Scutellaria
baicalensis Georgi; SR), and Rhei rhizome (rhizomes of Rheum officinale
Baill; RR). SHXXT was prepared by as follows: powdered crude
extracts of RR, SR and CR were weighed in a ratio of 2: 1: 1.
Each extract was added to 10-fold volume of water and then
boiled in different conditions individually. After finishing the
extraction, the materials were filtered to yield three extraction
solutions. Three hot solutions were combined and then condensed
to 1/20 in volume of the total original water. The new formed
condensed solution was spray-dried to get the final dry SHXXT.
SHXXT was dissolved in deionized distilled water along with LPS
for a 24 h incubation period. Simvastatin (1 mM; Sigma-Aldrich,
MO, USA) was dissolved in ETOH and was subsequently diluted
in saline. Both SHXXT and simvastatin were tested for the effect
on DNA methylation of the ERa gene in the HASMCs.
Animal Preparation
Eight-week-old Sprague-Dawley male rats were divided to three
groups (normal diet, high fat (HF) and HF plus SHXXT).
SHXXT (30 mg/kg/day) or placebo (water) was orally fed using
the ball-tipped feeding needle for 12 weeks. Rats were raised in a
Figure 6. Expression of miR-152 in LPS-treated HASMCs and the aorta of the Sprague-Dawley rats. (A) The miR-152 levels in the LPS -
treated HASMCs were examined by real-time quantitative PCR and normalized to RU6B after 48 h and 72 h treatment with/without SHXXT. (B) miR-
152 expression were detected by real-time quantitative PCR after treatment with simvastatin (1 mM). * P,0.05 versus the control group. Data
represents mean 6 SD from 3 independent experiments performed in triplicates. (C) miR-152 expression of the rat aorta evaluated by real-time
quantitative PCR. Rats under a high fat diet were treated with SHXXT (30 mg/kg/day) or placebo (water) for 12 weeks. The SD rat number of each
group is 6. Data represents mean 6 SD.
doi:10.1371/journal.pone.0030635.g006
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humidity and an artificial 12-h light-dark cycle. All animal
experiments were carried out in compliance with the ‘‘Guide for
the Care and Use of Laboratory Animals’’ published by the
National Academy of Sciences. The protocol was approved by the
Kaohsiung Medical University Animal Research Committee
(IACUC approval No.98018). After acclimatization for 1 week,
eighteen rats were randomly divided into 3 groups. The
composition of the HF diet was enriched with 30% fat. Access
to food and water was unrestricted for either group. The body
weight, food and water consumption of the animals were
measured daily. Rats were killed at the end of 12th week. Their
aortas were removed and immediately frozen in liquid nitrogen
until assayed.
PCR of Alu repetitive elements
Methylation analysis of Alu repetitive elements was performed
by the COBRA assay as described previously [41]. Methylation
quantification was performed with a molecular Dynamics
PhosphorImager.
Methylation specific PCR and sequencing
DNA was extracted from HASMCs and rat aortas by the DNA
extraction kit (Qiagen, CA, USA). Next, bisulfite conversion was
performed using the EZ DNA methylation Gold kit (Zymo
research, CA, USA) according to the manufacturer’s instructions.
Methylation specific PCR was then carried out to determine the
methylation status of ERa. Bisulphite-modified DNA was used for
PCR with primers specifically designed for methylated or
unmethylated sequences (Table 1). The PCR conditions were as
follows: 95uC for 5 min followed by 40 cycles of 95uC for 1 min,
56uC for 1 min and 72uC for 2 min, and then a final extension at
72uC for 7 min. PCR products were analyzed by electrophoresis
in a 2.0% agarose gel containing ethidium bromide.
Bisulfite sequencing of HASMC DNA samples was performed
as described previously [33]. The bisulfite-modified DNA was used
to amplify a 208-bp product of ERa exon 1 gene with primer sets
mentioned at Table 1. Two stage PCR were used to amplify a
region with in the ERa CpG island (GenBank accession
no. X03635.1 G1:31233). PCR products were cloned using
pGEM-T Vector System according the manufacturer’s instruc-
tions (Promega). The sequenced DNA region for ERa was
confirmed by using the automated sequencer (ABI automated
DNA sequencer).
RNA interference
We used shRNA to perform RNA interference. The lenti-viral
plasmids expressing 21-mer shRNAs against DNMT1 (clone ID:
TRCN0000021890) was obtained from the National RNAi Core
Facility in the Academia Sinica (Taipei, Taiwan). HASMCs were
transfected with the empty vector (pLKO.1 puro) or plasmids
expressing shRNA (6 mg DNA per 10
5 cells for 48 h) using
Lipofectamine 2000 (Invitrogen, CA, USA).
MicroRNA transfection
A negative control miRNA (#17110), hsa-miR-152 precursor
(Product ID: PM12269) and hsa-miR-152 inhibitor (Product ID:
AM12269) were purchased from the Ambion Inc. (TX, USA).
Figure 7. miR-152 regulates DNMT1 and ERa at the protein levels. LPS-treated HASMCs were transfected with miR-152 precursor/inhibitor
(25 nM and 100 nM) and a negative control miR (NC miR, 100 nM). (A) DNMT1 and ERaprotein levels were measured by Western blot at 72 h post-
transfection. (B) Exon 1 of the ERa methylation status was analyzed by MSP at 72 h post-transfection. UM: unmethylated; M: methylated ERa. (C)
HASMCs were incubated with LPS with the miR-152 precursor or inhibitor for 48 h and 72 h and the cell proliferation was assessed using the MTT
assay to measure mitochondrial enzyme activity.
# P,0.01 versus control, **P,0.01 versus the LPS group. Data represents mean 6 SD from 3
independent experiments performed in triplicates.
doi:10.1371/journal.pone.0030635.g007
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fectamine 2000.
RNA isolation, cDNA synthesis, and quantitative real-time
PCR
Total RNA was isolated from HASMCs and rat aortas using
Trizol reagent (Invitrogen, CA, USA). cDNA was synthesized by
reverse transcription with 1 mg RNA using the SuperScript
TM kit
(Invitrogen, CA, USA). The 20 ml reverse transcription products
were diluted to 100 ml and 2 to 3 ml was used for real-time PCR.
Real-time PCR reactions were performed in a volume of 25 ml
containing 140 ng specific primers (Table 1) and 12.5 ml SYBR
green Master Mix (ABI, CA, USA) using the following condition:
Initial denaturing: 95uC for 10 min, followed by 40 cycles of
denaturing at 95uC for 30 s, annealing at 56uC for 40 s, and
extension at 72uC for 30 s. The threshold cycle number (CT) value
for the target gene (DNMT1 and ERa) was normalized against
GAPDH and calculated as DCT=CT
Target2CT
GAPDH. Expres-
sion levels of mRNA were quantified by employing the 2
2DDCt
relative quantification method. Real-time PCR was performed for
Hsa-miR-152 (UCAGUGCAUGACAGAACUUGGG; Assay ID:
000438) using the specific TaqMan MiRNA Reverse Transcrip-
tion kit (Applied Biosystems). All the reactions were amplified on a
7900 HT Fast Real Time PCR system (Applied Biosystems).
Expression levels of miRNA were quantified employing the
2
2DDCt relative quantification method. The threshold cycle
number (CT) value for miR-152 was normalized against RU6B
and calculated as DCT=CT
miR-1522CT
RU6B. Expression levels
of miRNA were quantified by employing the 2
2DDCt relative
quantification method.
Western blot for DNMT1 and ERa
HASMCs were homogenized in 100 ml of protein extraction
reagent (Thermo Scientific, MA, USA) and protease inhibitor
(Panomics, CA, USA). Protein concentration was determined by
Pierce BCA Protein Assay Kit (Thermo Scientific, MA, USA).
20 mg of protein was loaded per lane and separated by NuPAGE
Novex Bis-Tris 4–12% mini gel electrophoresis (Invitrogen, CA,
USA) in the Novex Xcell-II apparatus for 120 min at 100 V, and
transferred to Immbilon-PVDF transfer membranes (Millipore,
MA, USA) for immunoblotting. Nonspecific binding was blocked
with 5% nonfat milk for 1 h at the room temperature. Bands were
visualized by reacting with specific antibodies for DNMT1 (Santa
Cruz biotechnology, CA, USA) and ERa (Millipore, MA, USA)
overnight at 4uC. Sequentially, the anti-mouse (for DNMT1) or
anti-rabbit (for ERa) secondary antibodies were conjugated to
horseradish peroxidase and enhanced chemiluminescence was
determined using Fuji medical X-ray film (Fujifilm, Tokyo, Japan).
Cell proliferation and migration assay
To examine the effect of miR-152 on cell proliferation,
HASMCs were transfected with the miR-152 precursor or
inhibitor and then were incubated in microplates at 37uC with
5% CO2 for 48 h and 72 h. After that 0.5 mg/ml of dimethyl-
thiazol- diphenyltetrazoliumbromide (MTT; Sigma-Aldrich, MO,
USA) was added into each well. Spectrophotometric readings were
performed by X340 spectrophotometer at 595 nm (Bio-TEK
Instruments, Inc., VT, USA). Migration assays were performed
following a standard protocol-wound repair assay. The mechanical
injury of confluent HASMCs and lesion repair assay were
performed as described elsewhere [42]. HASMCs were cultured
in 6-well plates at 2610
5 cells/well as confluent monolayers. The
monolayers were incubated and wounded in a line across the well
with a 200-ml standard pipette tip. The wounded monolayers were
washed twice with phosphate-buffered saline (PBS) and incubated
with serum-containing medium supplemented with LPS. The rate
of wound closure was measured and photographed over 24 h.
Statistics
All values in the text and figures are expressed as mean 6 SD.
Statistical differences were evaluated by Student’s t-test. A p
value,0.05 was considered statistically significant.
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Table 1. Primer sets.
Species Gene Primer Sequence
Human MSP for ERa Unmethylated-specific pair
F: 59-TGTTGTGTATAATTATTTTGAGGGT-39
R: 59-CTCACACACCATATAACCACTAAAC-39
Methylated-specific pair
F: 59-CGTCGTGTATAATTATTTCGAGGGC-39
R: 59-CTCGCGCACCGTATAACCGCTAAAC-39
BSP for ERa First round pair
F: 59-ATGGTTTTATTGTATTAGATTTAAGGGAAT-39
R: 59-TATTACICTAAACTCITTCTCCAAATAATA-39
Second round pair
F: 59-AGTGTATTTGGATAGTAGTAAG-39
R: 59-CTAACCITAAAACTACAAAAAAAA-39
PCR for
DNMT1 F: 59-GCACAAACTGACCTGCTTCA-39
R: 59-GCCTTTTCACCTCCATCAAA-39
ERa F: 59-TTCGGCTCCAACGGCCTGGGGGGTTT-39
R: 59-GGTACTGGCCAATCTTTCTCTGCCACCCT-39
GAPDH F: 59-GAAGGTGAAGGTCGGAGTC-39
R: 59-GAAGATGGTGATGGGATTTC-39
SD rat MSP for ERa Unmethylated-specific pair
F: 59-TGTTGTTGTTGTGTGGTTGTTGG-39
R: 59-TCAACAAACTAAACAACACAC-39
Methylated-specific pair
F: 59-TTAATTATTTCGAGGGCGTC-39
R: 59-AAAACGACGACACGTACGAC-39
PCR for
DNMT1 F: 59-ACCTACCACGCCGACAT-39
R: 59-AGGTCCTCTCCGTACTCCA-39
ERa F: 59-GGCTGCGCAAGTGTTACGAA-39
R: 59-CATTTCGGCCTTCCAAGTCAT-39
GAPDH F: 59-CCTTCATTGACCTCAACTAC-39
R: 59-GGAAGGCCATGCCAGTGAGC-39
doi:10.1371/journal.pone.0030635.t001
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